Skip to main content

Advertisement

Table 5 Outcomes in dCBT versus sCBT according to cell dose in multivariate analyses (adjusted for patient age, disease status, ALL versus AML, conditioning regimen, cytogenetic risk, and ATG)

From: Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT

  Hazard ratio 95% confidence interval P value
Lower limit Upper limit
Relapse
sCBT and TNC > median (ref)
dCBT and TNC > median 1.32 0.67 2.58 0.42
sCBT and TNC < median 1.99 1.02 3.89 0.04
dCBT and TNC < median 1.74 0.88 3.43 0.11
Nonrelapse mortality
sCBT and TNC > median (ref)
dCBT and TNC > median 0.69 0.35 1.36 0.29
sCBT and TNC < median 1.01 0.53 1.93 0.97
dCBT and TNC < median 0.93 0.47 1.83 0.84
Leukemia-free survival
sCBT and TNC > median (ref)
dCBT and TNC > median 0.97 0.61 1.55 0.89
sCBT and TNC < median 1.46 0.92 2.30 0.11
dCBT and TNC < median 1.27 0.79 2.03 0.33
Overall survival
sCBT and TNC > median (ref)
dCBT and TNC > median 0.97 0.60 1.58 0.91
sCBT and TNC < median 1.39 0.86 2.23 0.18
dCBT and TNC < median 1.07 0.65 1.77 0.78